Forskning ved Københavns Universitet - Københavns Universitet


A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Sabine Bélard
  • Saadou Issifou
  • Aurore B Hounkpatin
  • Frieder Schaumburg
  • Ulysse Ateba Ngoa
  • Meral Esen
  • Rolf Fendel
  • Pablo Martinez de Salazar
  • Raymund E Mürbeth
  • Paul Milligan
  • Nathalie Imbault
  • Egeruan Babatunde Imoukhuede
  • Theisen, Michael
  • Søren Jepsen
  • Ramadhani A Noor
  • Brenda Okech
  • Peter G Kremsner
  • Benjamin Mordmüller
GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.
TidsskriftP L o S One
Udgave nummer7
Sider (fra-til)e22525
StatusUdgivet - 2011

ID: 33889016